BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 25474743)

  • 1. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
    Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
    PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes.
    Lee DS; Park KR; Kim SJ; Chung MJ; Lee YH; Chang JH; Kang JH; Hong SH; Kim MS; Kim YS
    Tumour Biol; 2016 Jan; 37(1):619-25. PubMed ID: 26240025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features and prognostic factors in patients with bone metastases from non-small cell lung cancer.
    Wu XT; Zhou JW; Pan LC; Ge T
    J Int Med Res; 2020 May; 48(5):300060520925644. PubMed ID: 32425092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
    Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer.
    Tamiya M; Kobayashi M; Morimura O; Yasue T; Nakasuji T; Satomu M; Kohei O; Takayuki S; Morishita N; Suzuki H; Sasada S; Okamoto N; Hirashima T; Kawase I
    Clin Lung Cancer; 2013 Jan; 14(1):50-4. PubMed ID: 22609050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of pretreatment albumin-to-alkaline phosphatase ratio for overall survival for patients with advanced non-small cell lung cancer.
    Zhou S; Jiang W; Wang H; Wei N; Yu Q
    Cancer Med; 2020 Sep; 9(17):6268-6280. PubMed ID: 32691996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
    Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer.
    Imai H; Kaira K; Mori K; Ono A; Akamatsu H; Matsumoto S; Taira T; Kenmotsu H; Harada H; Naito T; Murakami H; Endo M; Nakajima T; Yamada M; Takahashi T
    BMC Cancer; 2015 Dec; 15():989. PubMed ID: 26690494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
    Fan J; Yu H; Lv Y; Yin L
    Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: a Fox Chase Cancer Center retrospective.
    Paralkar VR; Li T; Langer CJ
    Clin Lung Cancer; 2008 Mar; 9(2):116-21. PubMed ID: 18501099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
    Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.
    Wang B; Tu J; Yin J; Zou C; Wang J; Huang G; Xie X; Shen J
    Oncotarget; 2015 Nov; 6(35):38348-59. PubMed ID: 26435480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
    Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
    Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
    Taniguchi Y; Tamiya A; Isa SI; Nakahama K; Okishio K; Shiroyama T; Suzuki H; Inoue T; Tamiya M; Hirashima T; Imamura F; Atagi S
    Anticancer Res; 2017 Oct; 37(10):5857-5862. PubMed ID: 28982912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
    Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
    Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.